Arena Signs a Multi-Year Agreement with Beacon Discovery to Develop Therapies for Immune and Inflammatory Diseases
Shots:
- Beacon will take care of drug discovery activities while Arena will focus on development and commercialization of products for multiple immune and inflammatory diseases
- The focus of the agreement is to develop therapies for G protein-coupled receptor (GPCR) targets and further expanding the footprints in autoimmune diseases
- Arena has a pipeline of three candidates APD418- Olorinab- and Etrasimod. Etrasimod is a qd- PO- selective sphingosine 1-phosphate (S1P) receptor modulator targeted for multiple immune-mediated inflammatory diseases including UC- Crohn’s disease- and atopic dermatitis
Click here to read full press release/ article | Ref: Arena | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com